Eligibility. Applicants must meet the following criteria to qualify for a YIA: Be a physician (MD, DO, or international equivalent) working in any country and currently in the last two years of their ...

American Society of Clinical Oncology (ASCO) and Egyptian Cancer Society (ECS) leaders signed a Memorandum of Understanding (MOU) on June 2, 2025, during ASCO’s 61st Annual Meeting. The MOU formally ...

Meeting. 2023 ASCO Breakthrough. Session Type. Rapid Oral Abstract Session. Session Title. Rapid Abstract Session B: Precision Medicine and Multiomics. Track ...

[177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized ...

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:. On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, ...

The 2026 cycle opens July 1, 2025. All Conquer Cancer research grant applications are carefully reviewed and evaluated by an independent Grants Selection Committee (Committee) using consistent ...

While federal prior authorization reform legislation has yet to make it over the finish line and be enacted into law, state governments continue to pass legislation to mitigate the burdensome ...

CHICAGO — Results from the international phase 3 AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate (AKEEGA™) plus prednisone (AAP) can help slow cancer growth for people with ...

Decentralized clinical trial elements can be safely adopted as permanent fixtures without substantial reductions in data quality or increased risk to research participants, according to a new study in ...

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...

The Association for Clinical Oncology (ASCO) is outlining key priorities for the next generation of biomedical innovation policy in response to “A Roadmap for 21st Century Cures,” a white paper ...

The Association for Clinical Oncology (ASCO) is urging lawmakers to prioritize federal cancer research in Fiscal Year (FY) 2026 by providing the National Institutes of Health (NIH), National Cancer ...